Pediatric Bone Marrow Center

The Importance of Pediatric Bone Marrow Transplantation in Child Health

Pediatric Bone Marrow Transplantation is a life-saving treatment method that plays a vital role in the management of various hematological, oncological, and genetic diseases seen in childhood. This advanced therapeutic approach offered at our center involves the transplantation of healthy stem cells to replace diseased or dysfunctional blood cells. Its primary goal is to rebuild the patient’s hematopoietic system and restore normal function. 

PBMT has become a standard treatment approach for a wide spectrum of childhood conditions, ranging from blood cancers such as leukemia, to hematopoietic disorders like thalassemia and sickle cell disease, bone marrow failure syndromes such as aplastic anemia, and various genetic and immune system disorders. This informative article will comprehensively address the basic biology of stem cells, the stem cell transplantation process, specific diseases treated in the pediatric population, and the comprehensive services provided by our Pediatric Bone Marrow Transplant Center. 

Pediatric Stem Cell Transplantation Process: Stages and Approaches

The pediatric stem cell transplantation process consists of several carefully planned and meticulously implemented stages.

Pre-Transplant Conditioning Regimen

The first stage of the transplant process is referred to as the “conditioning regimen.” At this stage, careful adjustment of the medications and their doses is of great importance, taking into account the patient’s body weight, height, organ functions, and comorbidities. The conditioning regimen generally consists of high-dose chemotherapy and/or radiotherapy. The main objectives of this regimen are to eliminate residual cancer cells in the patient, prevent rejection of the infused stem cells, and create space in the bone marrow for the new cells. For the administration of stem cells, a special device called a central venous catheter, which is placed intravascularly, is usually used. 

Administration of Stem Cells to the Patient (Transfusion)

After completion of the conditioning regimen, stem cells are administered to the patient via the vascular route on the day of transplantation. Cryopreserved stem cells are thawed prior to infusion and promptly transferred to the patient. This procedure is performed in a manner similar to a blood transfusion, and certain medications may be administered beforehand to prevent allergic reactions or other potential side effects. 

Engraftment Process and Early Recovery Period

The infused stem cells are expected to migrate to the patient’s bone marrow, engraft, and proliferate. This process is referred to as “engraftment.” Once engraftment is successful, the patient’s blood counts begin to rise. However, this period is particularly challenging and requires close monitoring. Blood counts initially decrease, increasing the risk of infection, bleeding, and fatigue. To reduce these risks, supportive treatments such as blood and platelet transfusions and antibiotics are administered. In rare cases, stem cell engraftment may fail, necessitating a second transplant procedure. 

Post-Transplant Follow-up and Potential Complications

After discharge from the transplant unit, patients are enrolled in a regular and strict follow-up program at the transplant outpatient clinic. During the first three months, follow-up visits are scheduled weekly or biweekly, and regular monthly controls are required until the end of the first year. In the long term, the frequency of follow-up visits is determined based on the patient’s overall condition. 

Various complications may arise in the post-transplant period. These complications depend on many factors, including the type of disease, the type of transplant, the patient’s age, and the presence of comorbidities, and may sometimes be life-threatening. The main potential complications include: 

• Infections: Fever, cough, diarrhea, abdominal pain, shortness of breath, skin infections, or catheter-related infections may occur. 
  
• Gastrointestinal Problems: Nausea, vomiting, and fatigue are common side effects of treatment. 
  
• Organ Damage: Temporary or permanent damage to various organs may occur due to high-dose treatments. 
  
• Bone Marrow Failure: Insufficient production of new blood cells may be observed. 
  
• Graft Versus Host Disease (GVHD): This condition, seen in allogeneic transplants, occurs when donor cells recognize the patient’s normal tissues and organs as foreign and attack them. It may affect organs such as the skin, gastrointestinal tract, and liver. Severity varies and may require long-term treatment in some cases. 
  
• Other Complications: Rarer but serious risks include secondary malignancies, infertility, cataracts, disease relapse, and death. 

The diversity and potential severity of these post-transplant complications demonstrate that pediatric bone marrow transplantation is not merely a single surgical procedure, but rather a complex treatment process requiring intensive medical follow-up, multidisciplinary expertise, and long-term patient management. This explains why pediatric bone marrow transplant centers must invest not only in technological infrastructure but also in a broad range of specialized human resources and function similarly to intensive care units.

Diseases Treated with Pediatric Bone Marrow Transplantation

Pediatric bone marrow transplantation is an effective treatment method for numerous diseases of both malignant (malignant) and non-malignant (benign, usually hereditary) origin. The choice of transplant type is made carefully based on the nature of the disease and the patient’s overall condition. 

Diseases Treated with Allogeneic Stem Cell Transplantation

Allogeneic stem cell transplantation is preferred in cases where the patient’s own cells are diseased or insufficient. This type of transplant is particularly helpful in eliminating residual cancer cells that may remain despite chemotherapy and allows transplantation with cancer-free stem cells obtained from healthy donors. 

Malignant Diseases:

• Leukemias (Acute Myeloid Leukemia (AML), Chronic Myelocytic Leukemia (CML), Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia (CLL)). 
• Myelodysplastic Syndrome (MDS). 
• Non-Hodgkin lymphoma and Hodgkin lymphoma (in selected subgroups). 

Non-Malignant (Benign/Hereditary) Diseases:

• Hematopoietic Disorders: Aplastic Anemia, Fanconi Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Diamond-Blackfan Anemia, Thalassemia (Mediterranean Anemia), Sickle Cell Anemia. 
  
• Bone Marrow Failure: Conditions in which the bone marrow is unable to produce new blood cells. 
  
• Genetic Diseases: Mucopolysaccharidosis, Adrenoleukodystrophy, Metachromatic Leukodystrophy (MLD), Globoid cell leukodystrophy (Krabbe disease), Wolman disease, Osteopetrosis. 
  
• Immune System Disorders: Severe Combined Immunodeficiencies, Wiskott-Aldrich Syndrome, Hemophagocytic Lymphohistiocytosis, Kostmann Disease, Chronic Granulomatous Disease. 
  
• Inherited Aplastic Anemias: Dyskeratosis Congenita, Shwachman-Diamond Syndrome, Amegakaryocytic Thrombocytopenia. 

Diseases Treated with Autologous Stem Cell Transplantation

Autologous stem cell transplantation is performed in cases where the patient’s own stem cells are healthy and the primary problem is a malignancy that must be eradicated with high-dose chemotherapy. The main principle of this transplant type is to enable complete elimination of the disease through high-dose chemotherapy. 

• Acute Myeloid Leukemia (in selected subgroups). 
• Hodgkin Lymphoma and Non-Hodgkin Lymphoma. 
• Neuroblastoma. 
• Ewing sarcoma. 
• Medulloblastoma (brain tumors). 
• Soft Tissue Tumors. 
• Germ Cell Tumors. 
• Wilms’ Tumor (kidney tumor). 
• Retinoblastoma (eye tumor). 
• Some autoimmune diseases. 

The preference for autologous transplantation particularly in malignant diseases such as solid tumors and lymphomas reinforces the fact that this transplant type is used “to allow high-dose therapy,” with the primary aim of enabling more aggressive chemotherapy while preventing bone marrow damage through the patient’s own stem cells. In contrast, allogeneic transplantation highlights the critical role of “healthy” donor-derived cells in conditions such as genetic diseases and immune deficiencies, where the patient’s own cells are either diseased or insufficient. This distinction demonstrates that the choice of transplant type is directly related to the pathophysiology of the disease and requires individualized, precise medical decision-making for each patient.